Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,503.20
(
0.00%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
108.60
(
0.32%
)
Bitcoin
67,679.99
(
2.61%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 01/09/2008 10:50:45 PM

Wednesday, January 09, 2008 10:50:45 PM

Post# of 257302
IDIX vs VRUS:

In a monotherapy trial lasting 14 days, VRUS’ HCV drug, R7128, produced a mean reduction in viral load of 2.7 logs at the highest dose tested, which was 1500mg BID (#msg-25785397, scan to bottom of PR for monotherapy results).

In a monotherapy trial lasting only four days, IDIX’s HCV drug, IDX184, produced a reduction in viral load of 2.7-4.0 logs at a once-daily dose of 10mg/kg (#msg-25836250).

Alas, the IDX184 trial was only in animals. Nevertheless, based on early data it does not seem unreasonable to think that IDX184 may be as good a drug as R7128—if not better.

What about the two companies’ products for HBV? Well, IDIX is already receiving royalties from NVS on commercial sales of Tyzeka/Sebivo while VRUS’ HBV drug, Clevudine, is still in phase-3.

What about HIV? IDIX has an HIV drug in phase-2 called IDX899. VRUS probably has something going on in HIV, but I forget what.

Now look at the fully-diluted market caps of the two stocks: VRUS is approximately $600M while IDIX is <$200M, of which about $100M is cash on hand.

Which stock is the better biotech value at current prices?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today